- Home
- ACIC vs CSTL Comparison
ACIC vs CSTL Comparison
Compare ACIC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- CSTL
- Stock Information
- Founded
- ACIC 1999
- CSTL 2007
- Country
- ACIC United States
- CSTL United States
- Employees
- ACIC N/A
- CSTL N/A
- Industry
- ACIC Property-Casualty Insurers
- CSTL Medical Specialities
- Sector
- ACIC Finance
- CSTL Health Care
- Exchange
- ACIC Nasdaq
- CSTL Nasdaq
- Market Cap
- ACIC 556.0M
- CSTL 471.5M
- IPO Year
- ACIC N/A
- CSTL 2019
- Fundamental
- Price
- ACIC $10.24
- CSTL $15.32
- Analyst Decision
- ACIC Buy
- CSTL Strong Buy
- Analyst Count
- ACIC 1
- CSTL 6
- Target Price
- ACIC $16.00
- CSTL $37.67
- AVG Volume (30 Days)
- ACIC 144.2K
- CSTL 390.5K
- Earning Date
- ACIC 08-06-2025
- CSTL 08-04-2025
- Dividend Yield
- ACIC 4.89%
- CSTL N/A
- EPS Growth
- ACIC 3.21
- CSTL N/A
- EPS
- ACIC 1.49
- CSTL N/A
- Revenue
- ACIC $302,261,000.00
- CSTL $347,083,000.00
- Revenue This Year
- ACIC N/A
- CSTL N/A
- Revenue Next Year
- ACIC $37.63
- CSTL $1.62
- P/E Ratio
- ACIC $6.85
- CSTL N/A
- Revenue Growth
- ACIC 23.92
- CSTL 38.43
- 52 Week Low
- ACIC $8.82
- CSTL $14.60
- 52 Week High
- ACIC $15.08
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- ACIC 37.80
- CSTL 33.36
- Support Level
- ACIC $9.97
- CSTL $16.00
- Resistance Level
- ACIC $10.97
- CSTL $16.67
- Average True Range (ATR)
- ACIC 0.24
- CSTL 0.79
- MACD
- ACIC -0.06
- CSTL -0.25
- Stochastic Oscillator
- ACIC 25.00
- CSTL 15.99
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.